Dyslipidemia guidelines update
By
Ashraf Reda, MD, FESC
Prof and head of Cardiology Dep.
Menofiya University
LDL-C Goals for High Risk
Patients
Recommended LDL-C treatment goals
ATP III
Update 20041
<100 mg/dL:
Patients with CHD or...
ADA/ACC 2008 Consensus Statement:
Treatment Goals for Patients With
Cardiometabolic Risk and Lipoprotein Abnormalities
Goa...
ESC/EAS 2011
• Life style intervention should be tried first
• If not effective statin is the first choice
• Addition of C...
Calculating the risk: SCORE
• Very high, high, moderate or low risk
• Total and HDL-c are incorporated
• Relative risk cha...
LDL levels are the main target of lipid
management
• Less than 115 mg/dl in moderate risk
• Less than 100 mg/dl in high ri...
Atherogenic Lipoproteins
Non-HDL; Apo B100-containing

Non-HDL Includes All Atherogenic
Lipoprotein Classes
Very low-densi...
LIPID PROFILE
EGYPTIAN RF AND LIPID PROJECT
Non-HDL-c and Apo-B targets
• The goal for non HDL-c is 30 mg above LDL
goal
• Apo-B goal less than 80 mg/dl in very high ...
American Diabetes Association (2009)
Treatment recommendations and goals

• Statin therapy should be added to lifestyle
th...
American Diabetes Association (2009)
Treatment recommendations and goals

• In individuals without overt CVD, the
primary ...
Although there are no specific
goals , however Trigs., and HDL
are important risk determinant
Lipid Management in high TG:
Recommendation

l

lla llb lll

B
l

lla llb lll

B

l

C

lla llb lll

If TG are 200–499 mg/...
Elevated Triglycerides
Non-HDL Cholesterol: Secondary Target

• Primary target of therapy: LDL cholesterol
• Achieve LDL g...
Genetic dyslypidemia
• Familial combined hperlipidemia is not rare:
1% of population
• Often unrecognized and untreated
• ...
The issue of non-adherence
• Important barrier to dyslipidemia
management
• Responsibility of Pt. Dr., and health care
sys...
Implication of the new American
guidelines: which one should we
follow?

• ATP III 2002 JAMA (NHLBI)
• The new one (ACC/AH...
The new American guidelines: Key
features: Statin leeagable sub groups
•
•
•
•

Clinical Atherosclerotic CVD
LDL> 190 mg/d...
The new American guidelines: Sub groups with
doughtful benefits from statin

• > 75 yrs without clinical Atherosc. CVD
• A...
The American guidelines: key features
• High or moderate intensity statin therapy
when lipid lowering is indicated
• Dimin...
Guidelines are important but they are
just guidelines
Conclusions
•
•
•
•
•

More aggressive approach
Early screening and management
Incorporation of Tgs. And HDL in risk evalu...
Upcoming SlideShare
Loading in...5
×

Dyslipidemia guideline review : the transatlantic differences

836

Published on

ESC and ACC/AHA dyslipidemia guidelines

Published in: Health & Medicine
0 Comments
3 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
836
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
61
Comments
0
Likes
3
Embeds 0
No embeds

No notes for slide

Dyslipidemia guideline review : the transatlantic differences

  1. 1. Dyslipidemia guidelines update By Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University
  2. 2. LDL-C Goals for High Risk Patients Recommended LDL-C treatment goals ATP III Update 20041 <100 mg/dL: Patients with CHD or CHD risk equivalents (10 year risk >20%)1 <70 mg/dL: Therapeutic option for very high risk patients1 AHA/ACC guidelines for patients with CHD*,2 <100 mg/dL <70 mg/dL 2006 Update <100 mg/dL: Goal for all patients with CHD†,2 <70 mg/dL: A reasonable goal for all patients with CHD2 • If it is not possible to attain LDL-C <70 mg/dL because of a high baseline LDL-C, it generally is possible to achieve LDL-C reductions of >50% with more intensive LDL-C–lowering therapy, including drug combinations. * And other forms of atherosclerotic disease.2 † Factors that place a patient at very high risk: established cardiovascular disease plus: multiple major risk factors (especially diabetes); severe and poorly controlled risk factors (e.g., cigarette smoking); metabolic syndrome (triglycerides ≥200 mg/dL + non–HDL-C ≥130 mg/dL with HDL-C <40 mg/dL); and acute coronary syndromes.1 1. Grundy SM et al. Circulation 2004;110:227–239. 2. Smith SC Jr et al. Circulation 2006; 113:2363–2372.
  3. 3. ADA/ACC 2008 Consensus Statement: Treatment Goals for Patients With Cardiometabolic Risk and Lipoprotein Abnormalities Goals LDL-C Highest-Risk Patients Non–HDL-C Apo B <70 mg/dL <100 mg/dL <80 mg/dL <130 mg/dL <90 mg/dL • Known cardiovascular disease (CVD) • Diabetes plus ≥1 additional major CVD risk factor High-Risk Patients <100 mg/dL • No diabetes or known CVD but ≥2 major CVD risk factors • Diabetes but no other major CVD risk factors “In individuals on statin therapy who continue to have low HDL-C or elevated non–HDL- C, especially if Apo B levels remain elevated, combination therapy is recommended. The preferred agent to use in combination with a statin is nicotinic acid…” Reprinted from Brunzell JD, et al. J Am Coll Cardiol. 2008;51:1512–1524, with permission from Elsevier.
  4. 4. ESC/EAS 2011 • Life style intervention should be tried first • If not effective statin is the first choice • Addition of Ch. Absorption inhibitors, bile acid Seq. or niacin if not at goal
  5. 5. Calculating the risk: SCORE • Very high, high, moderate or low risk • Total and HDL-c are incorporated • Relative risk charts for young apparently low risk individuals • Charts for low and charts for high risk region • Charts for different HDL levels
  6. 6. LDL levels are the main target of lipid management • Less than 115 mg/dl in moderate risk • Less than 100 mg/dl in high risk • Less than 70 mg/dl in very high risk • If target can’t be achieved………50% reduction • Non-HDL-c and Apo-B potential targets in DM2, Met.S and combined dyslipidemia
  7. 7. Atherogenic Lipoproteins Non-HDL; Apo B100-containing Non-HDL Includes All Atherogenic Lipoprotein Classes Very low-density lipoprotein VLDL – Made in the liver – TG >> CE – Carries lipids from the liver to peripheral tissues Intermediate-density lipoprotein IDL LDL Lp(a) HDL – Formed from VLDL due to loss of TG – Also known as a VLDL remnant Low-density lipoprotein – Formed from IDL due to loss of TG – CE>>TG Lipoprotein (a) – Formed from LDL w/ addition of apo (a)? – Very atherogenic High-density lipoprotein – Removes cholesterol from peripheral tissues
  8. 8. LIPID PROFILE EGYPTIAN RF AND LIPID PROJECT
  9. 9. Non-HDL-c and Apo-B targets • The goal for non HDL-c is 30 mg above LDL goal • Apo-B goal less than 80 mg/dl in very high and less than 100 mg/dl in high risk • Especially considered as 2ry target in atherogenic dyslipidemia with average LDL
  10. 10. American Diabetes Association (2009) Treatment recommendations and goals • Statin therapy should be added to lifestyle therapy, regardless of baseline lipid levels, for diabetic patients: – with overt CVD – without CVD who are over the age of 40 and have one or more other CVD risk factors. DIABETES CARE, VOLUME 32, SUPPLEMENT 1, JANUARY 2009 Level of Evidence A A
  11. 11. American Diabetes Association (2009) Treatment recommendations and goals • In individuals without overt CVD, the primary goal is an LDL cholesterol 100 mg/dl. • In individuals with overt CVD, a lower LDL cholesterol goal of 70 mg/dl, using a high dose of a statin, is an option. • If drug-treated patients do not reach the above targets on maximal tolerated statin therapy, a reduction in LDL cholesterol of 30–40% from baseline is an alternative therapeutic goal. DIABETES CARE, VOLUME 32, SUPPLEMENT 1, JANUARY 2009 Level of Evidence A B A
  12. 12. Although there are no specific goals , however Trigs., and HDL are important risk determinant
  13. 13. Lipid Management in high TG: Recommendation l lla llb lll B l lla llb lll B l C lla llb lll If TG are 200–499 mg/dL, non-HDL-C should be <130 mg/dL Further reduction of non-HDL-C to <100 mg/dL is reasonable Therapeutic options to reduce non-HDL-C: More intense LDL-C–lowering therapy I (B) or Niacin (after LDL-C–lowering therapy) IIa (B) or Fibrate (after LDL-C–lowering therapy) IIa (B) If TG are >500 mg/dL, therapeutic options to prevent pancreatitis are fibrate or niacin before LDL lowering therapy; and treat LDL-C to goal after TG-lowering therapy, Achieve non-HDL-C <130 mg/dL, if possible TG=Triglycerides; HDL-C=high-density lipoprotein cholesterol Smith SC Jr et al. Circulation 2006;113:2363–2372.
  14. 14. Elevated Triglycerides Non-HDL Cholesterol: Secondary Target • Primary target of therapy: LDL cholesterol • Achieve LDL goal before treating non-HDL cholesterol • Therapeutic approaches to elevated non-HDL cholesterol – Intensify therapeutic lifestyle changes – Intensify LDL-lowering drug therapy – Nicotinic acid or fibrate therapy to lower VLDL
  15. 15. Genetic dyslypidemia • Familial combined hperlipidemia is not rare: 1% of population • Often unrecognized and untreated • Early detection and management
  16. 16. The issue of non-adherence • Important barrier to dyslipidemia management • Responsibility of Pt. Dr., and health care system
  17. 17. Implication of the new American guidelines: which one should we follow? • ATP III 2002 JAMA (NHLBI) • The new one (ACC/AHA/ NHLBI) • The hottest in AHA 2013 • Key feature: from specific lipid goal to % reduction
  18. 18. The new American guidelines: Key features: Statin leeagable sub groups • • • • Clinical Atherosclerotic CVD LDL> 190 mg/dl Type 1 or 2 DM & LDL> 70 mg/dl 10 year risk > 7.5% & LDL >70 mg/dl (New risk calculator)
  19. 19. The new American guidelines: Sub groups with doughtful benefits from statin • > 75 yrs without clinical Atherosc. CVD • A need for hemodialysis • Heart filure
  20. 20. The American guidelines: key features • High or moderate intensity statin therapy when lipid lowering is indicated • Diminished role of non statin lipid lowering agents alone or in combination • Avoid LL drugs in certain group • No routine LDL assessment • New risk calculator and extended use in primary prevention
  21. 21. Guidelines are important but they are just guidelines
  22. 22. Conclusions • • • • • More aggressive approach Early screening and management Incorporation of Tgs. And HDL in risk evaluation LDL is still the primary target Non HDL-c is a secondary target in DM2, Met.S and combined dyslipidemia • Is it the end of non statin LL agents and combination?
  1. ¿Le ha llamado la atención una diapositiva en particular?

    Recortar diapositivas es una manera útil de recopilar información importante para consultarla más tarde.

×